Wanbury Ltd Upgraded to Hold as Technicals and Financials Show Improvement

Technical Indicators Show Renewed Optimism

The primary catalyst behind the upgrade is Wanbury’s shift in technical trend from mildly bearish to mildly bullish. Weekly technical indicators have turned more favourable, with the Moving Average Convergence Divergence (MACD) on a weekly basis now mildly bullish, supported by bullish signals from Bollinger Bands and the Know Sure Thing (KST) indicator. The Dow Theory on a weekly scale also reflects a mildly bullish stance, while the On-Balance Volume (OBV) remains neutral weekly but bullish monthly.

Despite some mixed signals on the monthly charts—such as a mildly bearish MACD and KST—the overall technical momentum has improved enough to warrant a more positive outlook. The daily moving averages remain mildly bearish, suggesting some near-term caution, but the weekly and monthly trends indicate a potential medium-term uptrend. This technical improvement is underscored by the stock’s recent price action, with the current price at ₹252.45, up 4.99% on the day, and a 1-week return of 10.22% significantly outperforming the Sensex’s 3.70% gain.

Financial Trend Strengthens with Robust Profit Growth

Wanbury’s financial performance has been a key factor in the rating upgrade. The company reported positive results for three consecutive quarters, with the latest quarter (Q3 FY25-26) showing strong operating profit growth at an annualised rate of 107.56%. The profit after tax (PAT) for the nine months ended stood at ₹44.43 crores, reflecting an extraordinary growth of 332.20% year-on-year.

Operating profit to interest coverage ratio has reached a healthy 3.68 times, indicating improved ability to service debt. The debt-equity ratio at half-year stands at a relatively low 1.83 times, a significant improvement compared to the company’s average long-term debt-equity ratio of 3.36 times. This reduction in leverage enhances financial stability and reduces risk for shareholders.

However, it is important to note that despite these improvements, Wanbury remains a high-debt company with promoter share pledging at 86.67%, which could exert downward pressure on the stock in volatile markets.

Quality Assessment Reflects Long-Term Growth Potential

Wanbury’s quality metrics remain mixed but show encouraging signs. The company boasts a return on capital employed (ROCE) of 33.3%, which is attractive and suggests efficient utilisation of capital. Operating profit growth at an annual rate of 107.56% further supports the quality narrative. However, net sales growth over the past five years has been modest at 14.16% annually, indicating some challenges in top-line expansion.

Despite the high debt levels, the company’s ability to generate operating profits and improve interest coverage ratios points to improving operational quality. The PEG ratio of 0.1 indicates that the stock is undervalued relative to its earnings growth, which is a positive sign for long-term investors.

Valuation Remains Attractive Amid Discount to Peers

Wanbury’s valuation metrics support the Hold rating. The enterprise value to capital employed ratio stands at a low 4.7, signalling that the stock is trading at a discount compared to its peers’ historical averages. This valuation discount, combined with strong profit growth, makes the stock an attractive proposition for investors seeking value in the pharmaceuticals sector.

Over the past year, the stock has delivered a 5.50% return, outperforming the Sensex’s 2.25% gain, while profits surged by 252.3%. This divergence between earnings growth and stock price performance suggests room for multiple expansion if the company sustains its financial momentum.

Comparative Performance Highlights Long-Term Strength

Wanbury’s long-term returns have been exceptional relative to the broader market. Over the past three years, the stock has delivered a staggering 586.94% return compared to the Sensex’s 27.17%. Over five and ten years, the stock has also outperformed significantly, with returns of 151.69% and 357.75% respectively, versus Sensex gains of 58.30% and 199.87%.

This outperformance underscores the company’s ability to generate shareholder value over the long term despite short-term volatility and sector challenges. The recent upgrade to Hold reflects a recognition of this sustained growth trajectory combined with improving technical and financial fundamentals.

Risks and Considerations

Despite the positive developments, investors should remain cautious due to Wanbury’s high promoter share pledging at 86.67%, which can amplify downside risk in falling markets. The company’s average debt-equity ratio of 3.36 times also signals elevated leverage, which could constrain financial flexibility if earnings growth slows.

Moreover, the mixed technical signals on monthly charts and the mildly bearish daily moving averages suggest that the stock may face near-term volatility. Investors should monitor quarterly results and debt metrics closely to assess whether the company can sustain its recent momentum.

Conclusion

Wanbury Ltd’s upgrade from Sell to Hold by MarketsMOJO on 13 April 2026 is driven by a combination of improved technical indicators, robust financial performance, attractive valuation, and solid quality metrics. While the company faces challenges related to high debt and promoter pledging, its strong profit growth, operational improvements, and discounted valuation provide a balanced investment case.

For investors with a medium to long-term horizon, Wanbury offers a cautiously optimistic opportunity within the Pharmaceuticals & Biotechnology sector, supported by a Mojo Score of 64.0 and a Hold grade. Continued monitoring of technical trends and financial results will be essential to reassess the stock’s trajectory in the coming quarters.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today